These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
844 related articles for article (PubMed ID: 31046082)
41. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Muro K; Chung HC; Shankaran V; Geva R; Catenacci D; Gupta S; Eder JP; Golan T; Le DT; Burtness B; McRee AJ; Lin CC; Pathiraja K; Lunceford J; Emancipator K; Juco J; Koshiji M; Bang YJ Lancet Oncol; 2016 Jun; 17(6):717-726. PubMed ID: 27157491 [TBL] [Abstract][Full Text] [Related]
42. Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. Zamarin D; Walderich S; Holland A; Zhou Q; Iasonos AE; Torrisi JM; Merghoub T; Chesebrough LF; Mcdonnell AS; Gallagher JM; Li Y; Hollmann TJ; Grisham RN; Erskine CL; Block MS; Knutson KL; O'Cearbhaill RE; Aghajanian C; Konner JA J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503949 [TBL] [Abstract][Full Text] [Related]
43. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. Disis ML; Taylor MH; Kelly K; Beck JT; Gordon M; Moore KM; Patel MR; Chaves J; Park H; Mita AC; Hamilton EP; Annunziata CM; Grote HJ; von Heydebreck A; Grewal J; Chand V; Gulley JL JAMA Oncol; 2019 Mar; 5(3):393-401. PubMed ID: 30676622 [TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study. Oh DY; Algazi A; Capdevila J; Longo F; Miller W; Chun Bing JT; Bonilla CE; Chung HC; Guren TK; Lin CC; Motola-Kuba D; Shah M; Hadoux J; Yao L; Jin F; Norwood K; Lebellec L Cancer; 2023 Apr; 129(8):1195-1204. PubMed ID: 36748723 [TBL] [Abstract][Full Text] [Related]
45. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226 [TBL] [Abstract][Full Text] [Related]
47. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866 [TBL] [Abstract][Full Text] [Related]
48. Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases. Li Y; Yang Y; Shang YM; Zheng H Indian J Cancer; 2014 Mar; 51 Suppl 3():e92-4. PubMed ID: 25818742 [TBL] [Abstract][Full Text] [Related]
50. A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). Ngoi NY; Heong V; Ow S; Chay WY; Kim HS; Choi CH; Goss G; Goh JC; Tai BC; Lim DG; Kaliaperumal N; Au VB; Connolly JE; Kim JW; Friedlander M; Kim K; Tan DS Int J Gynecol Cancer; 2020 Aug; 30(8):1239-1242. PubMed ID: 32591370 [TBL] [Abstract][Full Text] [Related]
51. Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma. Yokota K; Takenouchi T; Fujisawa Y; Fukushima S; Uchi H; Inozume T; Kiyohara Y; Uhara H; Nakagawa K; Furukawa H; Han S; Watanabe M; Noguchi K; Yamazaki N J Dermatol; 2024 May; 51(5):632-642. PubMed ID: 38529706 [TBL] [Abstract][Full Text] [Related]
52. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Han SR; Noguchi K; Ebiana V; Hotta K Cancer Sci; 2020 Dec; 111(12):4480-4489. PubMed ID: 32926507 [TBL] [Abstract][Full Text] [Related]
53. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. O'Neil BH; Wallmark JM; Lorente D; Elez E; Raimbourg J; Gomez-Roca C; Ejadi S; Piha-Paul SA; Stein MN; Abdul Razak AR; Dotti K; Santoro A; Cohen RB; Gould M; Saraf S; Stein K; Han SW PLoS One; 2017; 12(12):e0189848. PubMed ID: 29284010 [TBL] [Abstract][Full Text] [Related]
54. PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab. Matsuki T; Kawakita D; Takahashi H; Okada T; Sakai A; Ueki Y; Tsuge H; Hanyu K; Momiyama K; Shodo R; Yamauchi M; Asako Y; Hirai H; Nagao T; Tada Y Sci Rep; 2024 Aug; 14(1):19794. PubMed ID: 39187586 [TBL] [Abstract][Full Text] [Related]
55. KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer. Nishio M; Takahashi T; Yoshioka H; Nakagawa K; Fukuhara T; Yamada K; Ichiki M; Tanaka H; Seto T; Sakai H; Kasahara K; Satouchi M; Han SR; Noguchi K; Shimamoto T; Kato T Cancer Sci; 2019 Mar; 110(3):1012-1020. PubMed ID: 30618179 [TBL] [Abstract][Full Text] [Related]
56. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®). Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331 [TBL] [Abstract][Full Text] [Related]
57. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. Colombo N; Dubot C; Lorusso D; Caceres MV; Hasegawa K; Shapira-Frommer R; Tewari KS; Salman P; Hoyos Usta E; Yañez E; Gümüş M; Olivera Hurtado de Mendoza M; Samouëlian V; Castonguay V; Arkhipov A; Toker S; Li K; Keefe SM; Monk BJ; N Engl J Med; 2021 Nov; 385(20):1856-1867. PubMed ID: 34534429 [TBL] [Abstract][Full Text] [Related]
58. Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. Zsiros E; Lynam S; Attwood KM; Wang C; Chilakapati S; Gomez EC; Liu S; Akers S; Lele S; Frederick PJ; Odunsi K JAMA Oncol; 2021 Jan; 7(1):78-85. PubMed ID: 33211063 [TBL] [Abstract][Full Text] [Related]
59. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520 [TBL] [Abstract][Full Text] [Related]
60. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer. Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]